Type II protein receptor serine/threonine kinases interact with transforming growth factor beta (TGFβ), bone morphogenic protein (BMP) or MÀllerian inhibiting substrate (MIS). Type II RSTKs then phosphorylate the kinase domain of their Type I RSTK partner - sometimes referred to as the signal propagating unit. This causes displacement of protein partners, such as the FKBP12 FK506-binding protein FKBP1A (P62942) and allowing the binding and phosphorylation of particular members of the Smad family.

* Key recommended reading is highlighted with an asterisk

* Batlle E, Massagué J. (2019) Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity, 50 (4): 924-940. DOI: 10.1016/j.immuni.2019.03.024 [PMID:30995507]

1. Berger C, Herrmann T, Lu C, Sheppard K-A, Trifilieff E, Urlinger S. (2013) Compositions and methods for increasing muscle growth. Patent number: US8388968. Assignee: Novartis Ag. Priority date: 27/04/2009. Publication date: 05/03/2013.